Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Turkaly
CJ
David Turkaly
Citizens JMP
Wall Street Analyst
★★★☆☆
#1509
on 13Foresight · ranked by our own returns
57%
Success Rate
+6.6%
Average Return
12 of 21 calls profitable · -14.6% vs benchmark
📈 Across the calls we could measure, roughly 57% of David Turkaly's ratings turned a profit when each position was held for 2 year — averaging +6.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

19 Buy 4 Hold 0 Sell
David's Stock Coverage 23 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
LNTH
Lantheus
 May 08, 2026 BUY Strong Buy
-27.9% avg upside
20 analysts
$115.00
10.65% Upside
 +12.5%
MDXG
MiMedx Group
 Apr 30, 2026 BUY Strong Buy
+185.0% avg upside
17 analysts
$6.00
63.52% Upside
 +7.3%
AXGN
AxoGen
 Apr 29, 2026 BUY Strong Buy
-25.8% avg upside
21 analysts
$50.00
11.51% Upside
 +6.7%
ZBH
Zimmer Biomet Holdings
 Apr 29, 2026 BUY Buy
+27.6% avg upside
37 analysts
$105.00
19.41% Upside
 +10.8%
TELA
TELA Bio
 Mar 27, 2026 BUY Strong Buy
+1010.3% avg upside
8 analysts
$3.00
274.59% Upside
 +47.8%
SYK
Stryker
 Dec 19, 2025 BUY Strong Buy
+24.1% avg upside
36 analysts
$440.00
43.04% Upside
 -14.1%
APYX
Apyx Medical
 Nov 12, 2025 BUY Strong Buy
+613.1% avg upside
10 analysts
$8.00
94.64% Upside
 -1.6%
KIDS
OrthoPediatrics
 Oct 10, 2025 BUY Strong Buy
+60.6% avg upside
10 analysts
$25.00
32.42% Upside
 +9.3%
GMED
Globus Medical
 Aug 20, 2025 HOLD Strong Buy
+22.3% avg upside
24 analysts
 — +32.4%
IART
Integra Lifesciences
 Aug 01, 2025 BUY Buy
+137.0% avg upside
21 analysts
$25.00
42.17% Upside
 +43.0%
STIM
Neuronetics
 Jul 28, 2025 BUY Strong Buy
+387.8% avg upside
6 analysts
$7.00
469.13% Upside
 -71.9%
HAE
Haemonetics
 May 20, 2025 BUY Buy
-8.8% avg upside
17 analysts
$100.00
34.90% Upside
 -15.1%
STE
Steris
 May 16, 2025 BUY Strong Buy
+22.1% avg upside
10 analysts
$280.00
38.18% Upside
 -16.6%
AVNS
Avanos Medical
 May 13, 2025 HOLD Buy
+9.6% avg upside
5 analysts
 — +94.4%
ENOV
Enovis
 May 09, 2025 BUY Strong Buy
+217.5% avg upside
37 analysts
$55.00
150.41% Upside
 -24.7%
SIBN
SI-Bone
 May 06, 2025 BUY Strong Buy
+60.9% avg upside
18 analysts
$32.00
101.98% Upside
 -13.9%
TFX
Teleflex
 Apr 02, 2025 HOLD Buy
+42.3% avg upside
19 analysts
 — -9.1%
OFIX
Orthofix Medical
 Mar 28, 2025 HOLD Strong Buy
+209.2% avg upside
15 analysts
 — -23.5%
ECOR
Electrocore
 Apr 06, 2023 HOLD Strong Buy
+537.6% avg upside
10 analysts
 — +1.2%
NHI
National Health Investors
 Jun 03, 2016 HOLD Buy
+6.2% avg upside
17 analysts
 — +15.6%
PMT
PennyMac Mortgage
 Jun 03, 2016 BUY Buy
+31.2% avg upside
13 analysts
$16.50
61.06% Upside
 +48.5%
ADAM
Adamas Trust
 Jun 03, 2016 HOLD Hold
+0.8% avg upside
14 analysts
 — ·
OSUR
Orasure Technologies
 Jun 25, 2009 HOLD Buy
+99.5% avg upside
11 analysts
 — ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Turkaly — Frequently Asked Questions
How accurate are David Turkaly's stock ratings?
Based on the calls 13Foresight could measure, about 57% of David's ratings were profitable over a one-year hold, with an average return of +5.2% per rating, or -12.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Turkaly is currently ranked #1509 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on LNTH, MDXG, AXGN, ZBH, TELA, SYK, APYX, KIDS, GMED, IART, STIM, HAE and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.